# Angiogenesis Forum I Efficacy Beyond Convention in Multiple Tumor Types



# Expanding options in treating mCRC with Anti-Angiogenesis



# Patrapim Sunpaweravong, MD.

Department of Internal Medicine, Prince of Songkla University

# **Education and Training**


| 1995       | Doctor of Medicine, Chulalongkorn University, Bangkok, Thailand                       |
|------------|---|
| 1999       | Diploma of Internal Medicine, Prince of Songkla University, Thailand                  |
| 2001       | Educational Commission for Foreign Medical, Graduates (ECFMG), Philadelphia, PA       |
| 2000 -2003 | Fellow in Medical Oncology, University of Colorado Health Sciences Center, Denver, CO |

# **Positions and Employment**

|  | i Usitiviis c  | Tositions and Employment  |  |  |
|--|--|---|--|--|
|  | 1995-1996<br>1996-1999<br>1999-2000<br>2000-2003<br>2003-2006<br>2006- | Medical Internship, Prince of Songkla University, Songkla, Thailand Medical Residency, Internal Medicine, Prince of Songkla University, Thailand Instructor, Department of Internal Medicine, Prince of Songkla University, Thailand Fellow, Division of Medical Oncology, Department of Medicine, University of Colorado Health Sciences Center, Denver, CO Instructor, Department of Internal Medicine, Prince of Songkla University, Thailand Assistant Professor, Department of Internal Medicine, Prince of Songkla University, Thailand |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
| *  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  | 5  |   |  |  |
|  |  |   |  |  |
| Ø.   |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
| 2  |  |   |  |  |
|  |  |   |  |  |
| *  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
| 0.000 mm.  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
|  |  |   |  |  |
| . 1  |  |   |  |  |
| The Mary   | -  |   |  |  |
| MARKE  |  |   |  |  |
| The state of the s | -  |   |  |  |
| THE WALL   |  |   |  |  |
|  | -  |   |  |  |
| pede   |  |   |  |  |
|  |  |   |  |  |



# We Innovate Healthcare



### Clinical Results in Metastatic Colorectal Cancer

- FOLFOX: increased activity in second line
   oxaliplatin-based: increased activity in first line
   cetuximab ± irinotecan: high activity in irinotecan
- bolus 5FU/LV + bevacizumab: not active in irinotecan

